Immix Biopharma Reports Unprecedented 100% ORR for CAR-T NXC-201 in AL Amyloidosis at ASH 2023

Immix Biopharma, Inc. IMMX, a rising name in the clinical-stage biopharmaceutical scene, has achieved a significant milestone in the treatment of AL Amyloidosis, as presented at the ASH 2023. The company's novel CAR-T therapy, NXC-201, has shown a remarkable 100% Overall Response Rate (ORR) in its updated Phase 1/2 study involving 10 patients with relapsed/refractory AL Amyloidosis. Remarkably, a 70% Complete Response (CR) rate was observed among the patients, all of whom had a history of multiple prior lines of therapy, specifically a median of six.

Stellar Performance in Treatment Efficacy

The impressive data, as of December 10, 2023, detail that the NXC-201 therapy is not just effective but also shows substantial sustainability in responses. Given the history of relapse and resistance to the standard of care (Dara-CyBorD), the complete response rate serves as an encouraging beacon of hope for patients afflicted by AL Amyloidosis. In addition, the duration of responses is ongoing, with the best response clocking in at 23.7 months for a continuously observed patient.

Immix Biopharma's Strategic Position

Headquartered in Los Angeles, California, with operations also in Australia, IMMX is allying innovation with purpose to create therapies that are not only tissue-specific but are also significantly altering the treatment paradigms in oncology and inflammation. The resounding success of NXC-201 serves as testament to their dedication and strategic focus in transforming the biopharmaceutical landscape.

Immix, Biopharma, AL-Amyloidosis, CAR-T, Therapy, 100%-ORR, ASH2023